<DOC>
	<DOC>NCT00329472</DOC>
	<brief_summary>This study is randomized phase III trial designed to assess whether (preoperative) neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (experimental treatment) improves 3-year disease-free survival, compared to surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (standard treatment) in stage IB, IIA, IIB and T3N1 non-small cell lung cancer</brief_summary>
	<brief_title>Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologically proven NSCLC patients All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest CT and PETCT 18 year of ages or older ECOG performance status 01 Unidimensionally measurable lesion by RECIST criteria No prior chemotherapy or radiotherapy for NSCLC Preoperative FEV1 ≥ 2.0 L evaluated within 28 days Adequate bone marrow function: Hb &gt; 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥ 100,000/μL Adequate liver and renal function: Total bilirubin &lt; 2 x ULN, AST/ALT &lt; 3 x ULN, serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min Written informed consent Superior sulcus tumor Prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia Recent myocardial infarction within 6 months Patients with postobstructive pneumonia or serious infection Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method.) Patients with psychological problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>